Cranial Remolding Orthosis Therapy for Positional Deformational Head Shape Abnormalities: The Parental Perspective

ObjectiveWe aimed to understand the impact of Cranial Remolding Orthotic therapy (CRO) on the quality of life of both infants with positional deformational head shape abnormalities (PDHSAs), including plagiocephaly and brachycephaly, and their caregivers.DesignSurvey study.SettingA single, tertiary academic center.Patients, ParticipantsFamilies of infants with PDHSAs who underwent CRO between 2007 and 2022.InterventionsCRO.Main Outcome Measure(s)Subjective assessment of caregiver perspectives.ResultsWe obtained 242 responses (72% male) from 1013 patients contacted (response rate 23.9%). CRO was initiated at a median age of 6 months (IQR 5-7 months), with a median treatment duration of 4 months (IQR 3-5 months). Insurance covered costs fully for 9.8% of respondents and partially for 47.0%; 43.2% paid completely out-of-pocket. Most were "very satisfied" or "satisfied" with head shape (89.2%) and ear position (93.3%). CRO did not impact children's sleep (75.2%), "never" or "rarely" impacted children's play (90.5%), and never impacted most families' attendance of social events (91.3%). Hair loss was temporary in 29.9% and permanent in 0.8%. Most families did not find CRO burdensome (73.1%) and "never" or "rarely" felt fatigued (68.5%).ConclusionsThe study sheds light on the mental and social effects of CRO on patients and caregivers, as well as physical adverse effects associated with treatment. Overall, patients' families expressed satisfaction with results and felt that administering CRO had minimal negative impacts on themselves and their children.